Cost-effectiveness of sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer in China. Kang S, Yang S, Jia Y, Zhao S, et al. PLoS One 2026;21:e0343330.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kang S, Yang S, Jia Y, Zhao S, et al. Cost-effectiveness of sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer in China. PLoS One 2026;21:e0343330.
PMID: 41790608